Replicating viruses as selective cancer therapeutics.

Replication-competent viruses are used as selective cancer therapeutics and the mechanisms leading to tumor-specific replication and antitumoral efficacy are now becoming apparent. The specific viruses in development include tumor-targeting herpes simplex viruses, autonomous parvoviruses, Newcastle disease viruses and adenovirus. Information is also available on antiviral immunology and viral defenses against host-mediated immunity. This approach has many potential attributes, in addition to potential hurdles that must be overcome.

[1]  J. Rommelaere,et al.  Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein , 1994, Journal of virology.

[2]  Gooding Lr.  Regulation of TNF-mediated cell death and inflammation by human adenoviruses. , 1994 .

[3]  J. Goldie,et al.  Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. , 1994, Journal of the National Cancer Institute.

[4]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[5]  G. Trinchieri,et al.  Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung , 1995, Nature Medicine.

[6]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[7]  R. Vile,et al.  Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. , 1995, Virology.

[8]  B. Harvey,et al.  "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. , 1996, Human gene therapy.

[9]  Michael B. Fernando,et al.  Newcastle disease virus selectively kills human tumor cells. , 1992, The Journal of surgical research.

[10]  J. Rommelaere,et al.  Antineoplasic activity of parvoviruses , 1991 .

[11]  R. Huebner,et al.  Studies on the use of viruses in the treatment of carcinoma of the cervix , 1956 .

[12]  C. Southam,et al.  Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus , 1952, Cancer.

[13]  C. Smith,et al.  Viruses in the treatment of cancer. , 1970, Lancet.

[14]  A. Berk,et al.  Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. , 1987, Virology.

[15]  G. Prince,et al.  The molecular basis of adenovirus pathogenesis. , 1994, Infectious agents and disease.

[16]  J. Rommelaere,et al.  The nonstructural proteins of the autonomous parvovirus minute virus of mice interfere with the cell cycle, inducing accumulation in G2. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[17]  D. Murray,et al.  A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate , 1983, Cancer.

[18]  M. Peeples,et al.  Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. , 1994, Journal of the National Cancer Institute.

[19]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[20]  G. Winter,et al.  Retroviral vectors displaying functional antibody fragments. , 1993, Nucleic acids research.

[21]  T. Asada.  Treatment of human cancer with mumps virus , 1974, Cancer.

[22]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Y. Kan,et al.  Ligand-directed retroviral targeting of human breast cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Gooding,et al.  Cytolysis of adenovirus-infected murine fibroblasts by IFN-gamma-primed macrophages is TNF- and contact-dependent. , 1994, Cellular Immunology.

[25]  R. Tripp,et al.  Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes , 1993, Journal of virology.

[26]  Rolf M. Zinkernagel,et al.  Immunology Taught by Viruses , 1996, Science.

[27]  D. Larsimont,et al.  Parvovirus H‐1 inhibits growth of short‐term tumor‐derived but not normal mammary tissue cultures , 1993, International journal of cancer.

[28]  B. Vogelstein,et al.  Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. , 1988, Cancer research.